欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

Others

货号 产品名 CAS号 信息
CSN91707 Naxitamab 1879925-92-4 Naxitamab is a humanised (IgG1) anti-GD2 (hu3F8) monoclonal antibody was developed by the Memorial Sloan Kettering Cancer Center (with commercial rights licenced to Y-mAbs therapeutics Inc.) for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers.
CSN123417 Human IgG1 kappa, Isotype Control Human IgG1 kappa is an isotype control for human IgG1κ antibody.
CSN103691 BCI-137 112170-24-8 BCI-137 is an Argonaute 2 (Ago2) ligand that acts by targeting the MicroRNA Binding Domain.
CSN_mab1008 Denosumab (anti-TNFSF11) 615258-40-7
CSN_mab1021 Omalizumab 242138-07-4
CSN_mab1034 Ixekizumab 1143503-69-8
CSN73098 Fresolimumab 948564-73-6
CSN73487 Eculizumab 219685-50-4
CSN76132 Evolocumab 1256937-27-5
CSN78368 Sacituzumab 1796566-95-4
CSN87233 Blosozumab 1132758-87-2
CSN87862 Brentuximab 2088770-90-3
CSN89703 Olokizumab 1007223-17-7
CSN89706 Lirilumab 1000676-41-4
CSN90222 Ficlatuzumab 1174900-84-5
CSN90223 Etrolizumab 1044758-60-2
CSN91655 Bococizumab 1407495-02-6
CSN91697 Foralumab 946415-64-1
CSN91704 Lenzilumab 1229575-09-0
CSN91679 Cixutumumab 947687-12-9
CSN91664 Enokizumab 909875-08-7
CSN91683 Motavizumab 677010-34-3
CSN91645 Eldelumab 946414-98-8
CSN91674 Evinacumab 1446419-85-7
CSN91663 Sifalimumab 1006877-41-3
CSN91638 Abrilumab 1342290-43-0
CSN91669 Bapineuzumab 648895-38-9
CSN91694 Abituzumab 1105038-73-0
CSN90398 Glembatumumab 1020264-78-1
CSN90386 Fletikumab 1357158-22-5
CSN91678 Emibetuzumab 1365287-97-3
CSN91635 Carlumab 915404-94-3
CSN91703 Fasinumab 1190239-42-9
CSN92830 Figitumumab 943453-46-1
CSN38757 Fmoc-1,6-diaminohexane 166410-37-3
CSN38465 Lapaquistat 189059-71-0
CSN37787 BPH-652 157124-84-0
CSC33297 Dextran 9004-54-0
CSC68807 Dextran 9004-54-0
CSN61973 SR-0813 2597186-19-9
CSN62643 Fmoc-Tyr(3-F,tBu)-OH 2254698-84-3
CSN67039 TSPC 882286-32-0
CSN80975 Actinoquinol 15301-40-3
CSN105512 BMS 188745 Potassium Salt 157126-15-3
CSN102474 Advastab TM 188 26401-97-8
<< PREV 1 2 3 4 5 6 7 8 9 NEXT >>
联系
我们